Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib second-line treatment after checkpoint inhibitor therapy in advanced clear-cell renal cell carcinoma
2018-002820-18Phase 2Active
- Sponsor
- Ipsen
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in renal cell carcinoma (RCC), sponsored by Ipsen. Primary endpoint: Objective response rate. Started Jun 2019; status: active.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2018-002820-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002820-18.